Chris Hollowood
Chris is the Chief Executive Officer of Syncona Investment Management Ltd.
He brings with him over 20 years of life science investment experience, having been with Syncona since it was launched in 2012, where he was Chief Investment Officer until 2022, and has led the development of its gene therapy strategy, founding companies across ocular, hepatic, renal and central nervous system therapeutics.
He is Chairman of Spur and a Board member of Beacon, Yellowstone and Purespring. He was previously Chairman of retinal gene therapies Nightstar, which was sold to Biogen in 2019 for $877 million, and Gyroscope, which was sold to Novartis for $800 million in 2022.
Previously, Chris was a partner at Apposite Capital LLP and held roles with Bioscience Managers Ltd, Neptune Investment Management Ltd and in the pharmaceutical industry. Chris holds a degree in Natural Sciences and a PhD in Organic Chemistry, both from the University of Cambridge.
Syncona portfolio companies
- Spur Therapeutics (Chair)
- Beacon Therapeutics (Board member)
- Yellowstone Biosciences (Board member)
- Purespring Therapeutics (Director)
